Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
IMVT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$19.07 - $39.55
Previous CloseN/A
Volume171.97K
Average Volume (3M)1.39M
Market Cap
$3.47B
Enterprise Value$3.26B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.70
Next Earnings
May 28, 2025EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.62
Shares Outstanding169,860,690
10 Day Avg. Volume1,565,948
30 Day Avg. Volume1,387,957
Standard Deviation0.23
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.13K
Enterprise Value/Ebitda-9.27
Forecast
1Y Price Target
$47.88Price Target Upside134.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Immunovant News
PremiumCompany Announcements
Immunovant Reports Progress Amid Increased R&D Costs
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentImmunovant's IMVT-1402 is advancing with six investigational new drug applications cleared, utilizing YpsoMate autoinjector technology.
Financial StabilityThe company reported a pro forma cash balance of ~$825M, indicating sufficient funding to complete late-stage studies.
Market PositionImmunovant is a first mover or early mover within the FcRn class for large market indications such as Graves' disease and rheumatoid arthritis.
Bears Say
Clinical EfficacyThe correlation between the depth of IgG lowering and response in myasthenia gravis has been mixed based on prior FcRn readouts.
Market CompetitionShort interest is relatively high at 19.5%.
Regulatory RisksThere are several risk factors that could impact the stock rating and price target, including success and visibility of IMVT-1402, competition, and regulatory risks.
---
Ownership Overview
2.73% Insiders
15.46% Mutual Funds
24.73% Other Institutional Investors
49.22% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMVT FAQ
What was Immunovant’s price range in the past 12 months?
Immunovant lowest stock price was $19.07 and its highest was $39.55 in the past 12 months.
What is Immunovant’s market cap?
Immunovant’s market cap is $3.47B.
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is May 28, 2025 which is in 95 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on Feb 06, 2025. The company reported -$0.76 earnings per share for the quarter, missing the consensus estimate of -$0.752 by -$0.008.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -0.71.
How many shares outstanding does Immunovant have?
Immunovant has 169,860,690 shares outstanding.
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -$0.76 in its last earnings report, missing expectations of -$0.752. Following the earnings report the stock price went down -9.551%.
Which hedge fund is a major shareholder of Immunovant?
Currently, no hedge funds are holding shares in IMVT
---
Immunovant Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.88 (134.13% Upside)
$47.88 (134.13% Upside)
Blogger Sentiment
Bullish
IMVT Sentiment 75%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $335.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.46%
12-Months-Change
Fundamentals
Return on Equity
-74.17%
Trailing 12-Months
Asset Growth
-40.83%
Trailing 12-Months
Company Description
Immunovant
Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.
---
IMVT Stock 12 Month Forecast
Average Price Target
$47.88
▲(134.13% Upside)
Technical Analysis
Best Analysts Covering IMVT
1 Year
1 Year Success Rate
10/18 ratings generated profit
1 Year Average Return
+82.89%
reiterated a buy rating 16 days ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +82.89% per trade.
---